Teva, Barr And Watson Launch Generics Of Merck’s Fosamax
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson's authorized alendronate generic eases sting of lost exclusivity for the blockbuster osteoporosis drug.
You may also be interested in...
Novartis’ Phase III Bone Drug Reclast Beats Actonel
Company seeks FDA clearance for treatment and prevention of steroid-induced osteoporosis.
Novartis’ Phase III Bone Drug Reclast Beats Actonel
Company seeks FDA clearance for treatment and prevention of steroid-induced osteoporosis.
Bisphosphonate Marketers Push Dosing Advantages After Feb. 6 Fosamax Patent Expiry
Branded osteoporosis drug makers gird for a hit from launch of a low-cost version of Merck’s market leading alendronate.